{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Pittsburgh&page=31&state=Pennsylvania",
    "query": {
      "state": "Pennsylvania",
      "city": "Pittsburgh",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 10627,
    "total_pages": 1063,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Pittsburgh&page=32&state=Pennsylvania&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Pittsburgh&page=30&state=Pennsylvania&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T20:14:32.340Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05017701",
      "title": "Feasibility of Bridge for Post-Operative Pain Management in Hip Arthroplasty",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Bridge device",
          "type": "DEVICE"
        },
        {
          "name": "Sham device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Masimo Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-04-26",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05017701"
    },
    {
      "nct_id": "NCT03290781",
      "title": "An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Ontamalimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "81 Years",
        "sex": "ALL",
        "summary": "16 Years to 81 Years"
      },
      "enrollment_count": 366,
      "start_date": "2018-04-04",
      "completion_date": "2021-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 94,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 80 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03290781"
    },
    {
      "nct_id": "NCT03643965",
      "title": "Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Nefecon",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2018-09-05",
      "completion_date": "2023-07-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03643965"
    },
    {
      "nct_id": "NCT01182636",
      "title": "Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Adapalene",
          "type": "DRUG"
        },
        {
          "name": "Differin®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 601,
      "start_date": "2007-07",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2010-11-24",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182636"
    },
    {
      "nct_id": "NCT05947071",
      "title": "High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection",
        "Transplantation Infection",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 312,
      "start_date": "2024-09-26",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 11,
      "location_summary": "Stanford, California • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05947071"
    },
    {
      "nct_id": "NCT01632137",
      "title": "Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "Rebamipide 2% ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kubota Vision Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 564,
      "start_date": "2012-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-07",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01632137"
    },
    {
      "nct_id": "NCT02990572",
      "title": "Amish/Mennonite Research Contact Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2016-10",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02990572"
    },
    {
      "nct_id": "NCT06070012",
      "title": "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "Tebentafusp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diwakar Davar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2025-08-18",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06070012"
    },
    {
      "nct_id": "NCT06919965",
      "title": "A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "TAR-210",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin C",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2025-09-10",
      "completion_date": "2032-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 27,
      "location_summary": "Sun City, Arizona • Los Angeles, California • Lakewood, Colorado + 23 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06919965"
    },
    {
      "nct_id": "NCT00235300",
      "title": "An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cadaveric Donor Renal Transplantation",
        "Acute Renal Allograft Rejection",
        "Induction Therapy"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin [Anti-thymocyte Globulin (rabbit)]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Simulect (basliximab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2000-05",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-11-07T20:14:32.340Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235300"
    }
  ]
}